# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

### **IN THE CLAIMS:**

Please amend the claims as follows:

### 1-16. (canceled)

- 17. (currently amended) A method for screening compounds for receptor tyrosine kinase (RTK) agonists or RTK antagonists comprising:
  - (a) crystallizing a modified RTK polypeptide, said modified RTK polypeptide
    having kinase activity and comprising RTK kinase domain α helix D
    linked to RTK kinase domain α helix E by a truncated RTK kinase insert
    domain (KID);
  - (b) obtaining crystallography coordinates for said modified RTK polypeptide;
  - (c) applying said crystallography coordinates for said modified RTK polypeptide in order to generate a model of said modified RTK polypeptide suitable for use in designing molecules compounds that will act as agonists or antagonists to said modified RTK polypeptide; and
  - (d) applying an iterative process whereby various molecular structures are applied to said model to identify agonists or antagonists to said modified RTK polypeptide.
- 18. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 50 residues from the KID.
- 19. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 60 residues from the KID.
- 20. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of the highly charged residues from the KID.
- 21. (previously presented) The method of claim 17 wherein said truncated kinase insert domain linking said α helix D to said α helix E is of a sufficient length so as

to allow said helices to maintain appropriate conformation associated with competent kinase structure.

- 22. (currently amended) The method of claim 17 wherein said RTK polypeptide is a member of the platelet derived growth factor receptor (PDGFR) family.
- 23. (currently amended) The method of claim 22 wherein said PDGFR member is selected from the group consisting of <u>vascular endothelial growth factor receptor</u> (VEGFR)-1, <u>VEGFR-2</u> VEFGR-2, PDGFR-α, PDGFR-β, stem cell growth factor receptor (c-kit), and colony stimulating factor-1 receptor (CSF-1R/c-fms).
- 24. (previously presented) The method of claim 22 wherein said RTK polypeptide is selected from the group consisting of insulin receptor (IRK), fibroblast growth factor receptor-1 (FGFR-1), and VEGFR-2.
- 25. (previously presented) The method of claim 17 wherein said RTK polypeptide is VEGFR-2.
- 26. (previously presented) The method of claim 17 wherein said modified RTK polypeptide comprises VEGFR2Δ50 polypeptide of SEQ ID NO: 5.